Navepegritide

What is Navepegritide?

Navepegritide is a sustained-release prodrug of C-type natriuretic peptide (CNP), developed by Ascendis Pharma and marketed as YUVIWEL. It was approved by the FDA on 27 February 2026 under accelerated approval to increase linear growth in pediatric patients 2 years of age and older who have achondroplasia with open epiphyses — the second drug ever approved for achondroplasia, after BioMarin's vosoritide (Voxzogo) in 2021, and the first to be given once weekly instead of once daily. The design problem navepegritide solves is CNP's half-life. Native CNP-22 survives only about two to three minutes in plasma because neprilysin and the NPR-C clearance receptor strip it out almost immediately, which is why nobody has ever developed native CNP as a systemic drug. Vosoritide solved this by re-engineering the peptide itself: it is a 39-residue analog with an N-terminal extension that resists neprilysin cleavage, enough to support daily injection. Ascendis took the opposite approach. Rather than modify the peptide's pharmacology, it uses the TransCon ('transient conjugation') platform to hide an unmodified CNP payload — CNP(89-126), a 38-residue form usually written CNP-38 — on an inert methoxy-polyethylene-glycol carrier via a linker that hydrolyses at a predictable rate. The conjugate is pharmacologically silent; the linker slowly releases free, unmodified CNP-38 across the dosing interval. The intended result is continuous CNP exposure between weekly injections rather than the daily peak-and-trough profile of an engineered analog. Whether continuous exposure is clinically better than daily pulses is genuinely unresolved. The pivotal ApproaCH trial showed a 1.49 cm/year improvement in annualized growth velocity versus placebo — statistically robust, and numerically close to vosoritide's 1.57 cm/year, though the two trials enrolled non-overlapping age ranges and no head-to-head study has ever been run. Navepegritide's clearest advantages are practical rather than pharmacological: one injection a week instead of seven, and no requirement to eat and drink before dosing.

What Navepegritide Is Investigated For

Navepegritide has exactly one approved use: increasing linear growth in children aged 2 and older who have achondroplasia with open epiphyses. The pivotal evidence is ApproaCH (NCT05598320), a randomized, double-blind, placebo-controlled trial that enrolled 84 treatment-naïve children aged 2 to 11 (mean age 5.7 years, mean baseline CDC height Z-score −5.0) across ten hospitals in Australia, Canada, Denmark, Ireland, New Zealand, Spain, and the United States, randomized 2:1 to navepegritide 100 mcg/kg weekly or placebo for 52 weeks. The primary endpoint was met: annualized growth velocity was 5.9 cm/year on treatment versus 4.4 on placebo, a least-squares mean difference of 1.49 cm/year (95% CI 1.05–1.93, p<0.001). Secondary endpoints moved in the expected directions — achondroplasia-specific height Z-score +0.3 versus 0.0, tibial-femoral angle −1.81 degrees, mechanical axis deviation −2.78 mm — and there were no treatment-related serious adverse events and no deaths. Supporting data come from ACcomplisH, the Phase 2 dose-escalation trial (57 children), whose open-label extension maintained growth velocity through two years at the 100 mcg/kg weekly dose. The caveats matter as much as the result, and families deserve them plainly. This is an accelerated approval resting on annualized growth velocity, a surrogate endpoint; continued approval is contingent on confirmatory trials, and no adult-height data exist for navepegritide or for any CNP analog. The growth effect was age-dependent in ApproaCH itself — 1.0 cm/year in children under 5 versus 1.8 cm/year in those 5 and over — which complicates any simple extrapolation across a childhood of treatment. A 2026 meta-analysis pooling both approved CNP analogs across 11 studies and 542 patients put the class effect at +1.36 cm/year and described the improvements as 'slight but statistically meaningful,' which is a fair summary. Nothing yet shows that navepegritide reduces the complications that actually drive morbidity in achondroplasia — foramen magnum stenosis, spinal stenosis, sleep apnea. And as with vosoritide, whether to treat at all is a values question on which the achondroplasia community holds a genuine range of views, not a purely medical one.

History & Discovery

Navepegritide is the product of two independent lines of work converging: three decades of CNP growth-plate biology, and Ascendis Pharma's TransCon prodrug platform. The biology came first. CNP was identified in 1990 by Sudoh, Minamino, Kangawa, and Matsuo in Japan as the third member of the natriuretic peptide family. Over the following decade its dominant physiological role turned out to be skeletal rather than cardiovascular: Chusho and colleagues showed in 2001 that CNP-knockout mice develop severe dwarfism, Miyazawa and colleagues established PKG-II as the required downstream effector in chondrocytes, and in 2004 Yasoda and colleagues demonstrated in Nature Medicine that chondrocyte-targeted CNP overexpression rescues the achondroplasia phenotype in Fgfr3-mutant mice through cGMP-mediated antagonism of MAPK signaling. Human genetics confirmed the pathway's dosage sensitivity in both directions — loss-of-function NPPC or NPR2 mutations cause acromesomelic dysplasia type Maroteaux, while activating NPR2 mutations produce extreme tall stature without skeletal deformity. By the mid-2000s the therapeutic logic was clear and the obstacle was purely pharmacokinetic: native CNP survives two to three minutes in plasma. BioMarin got there first by re-engineering the peptide. Vosoritide (BMN-111) added an N-terminal extension that resists neprilysin cleavage, cleared Phase 3 in 2020, and was approved as Voxzogo in November 2021 for children aged 5 and older with open epiphyses, expanded in October 2023 down to 4 months — the first pharmacological therapy ever approved for achondroplasia. Ascendis approached the same target from its platform rather than from the peptide. TransCon — 'transient conjugation' — attaches an unmodified parent drug to an inert carrier through a linker engineered to hydrolyse at a predictable rate, so that the conjugate is pharmacologically silent and the parent molecule is released slowly and unmodified. The company had already validated the platform twice: lonapegsomatropin (TransCon hGH, SKYTROFA) was FDA-approved for pediatric growth hormone deficiency in August 2021, and palopegteriparatide (TransCon PTH, YORVIPATH) for adult hypoparathyroidism in August 2024. Applying it to CNP, Ascendis conjugated a CNP(89-126) payload to a methoxy-PEG carrier. Breinholt and colleagues published the preclinical characterization in 2019 (J Pharmacol Exp Ther) and the first-in-human Phase 1 results in 2022 (Br J Clin Pharmacol). Clinical development ran through two trials named in the company's habitual style. ACcomplisH (NCT04085523), the Phase 2 dose-escalation study in 57 children published in EClinicalMedicine in 2023, spanned 6 to 100 mcg/kg weekly and selected the top dose. ApproaCH (NCT05598320) enrolled 84 treatment-naïve children aged 2 to 11 between March and August 2023 across ten hospitals in Australia, Canada, Denmark, Ireland, New Zealand, Spain, and the United States, randomized 2:1 to navepegritide 100 mcg/kg weekly or placebo for 52 weeks double-blind followed by an open-label extension. It met its primary endpoint — a least-squares mean annualized-growth-velocity difference of 1.49 cm/year (95% CI 1.05–1.93, p<0.001) — and was published in JAMA Pediatrics in January 2026. The FDA granted accelerated approval on 27 February 2026 under NDA 219164, for increasing linear growth in pediatric patients aged 2 and older with achondroplasia and open epiphyses, with continued approval contingent on confirmatory verification of clinical benefit. YUVIWEL launched in the United States in the first half of 2026; Ascendis reported €8 million in second-quarter 2026 revenue against more than 170 unique US patient enrollments through 30 June and more than 220 through the end of July, with over 65% approved for reimbursement. The achondroplasia treatment landscape is now genuinely competitive for the first time, and not only between the two injectables. In June 2026 the New England Journal of Medicine published PROPEL 3, BridgeBio's Phase 3 trial of oral infigratinib — an FGFR3 tyrosine kinase inhibitor that attacks the over-active receptor directly rather than antagonising it downstream through NPR-B. An oral option would change the calculus for families weighing weekly versus daily injections, which is currently navepegritide's principal advantage.

How It Works

Children with achondroplasia have a genetic change that makes a protein called FGFR3 overactive. Overactive FGFR3 tells the cartilage cells in the growth plates at the ends of long bones to slow down, which is why arms and legs stay short. C-type natriuretic peptide, or CNP, is the body's natural signal that pushes those same cells to keep growing — it works through a different receptor and cancels out part of the FGFR3 signal. The problem is that natural CNP is destroyed within a couple of minutes of entering the bloodstream. Navepegritide gets around this by hiding a normal CNP molecule on an inert carrier attached by a linker that slowly comes apart. Once injected, the linker releases free CNP a little at a time over the following week, so one shot covers seven days instead of needing a daily injection.

Achondroplasia is caused by a recurrent gain-of-function mutation in FGFR3 — most commonly G380R — that constitutively activates the RAS–RAF–MEK–ERK MAPK cascade in growth-plate chondrocytes. Over-active MAPK signaling suppresses chondrocyte proliferation, differentiation, and hypertrophy, shortening the proliferative and hypertrophic zones of the growth plate and blunting endochondral ossification. CNP signals through natriuretic peptide receptor B (NPR-B, also called GC-B or NPR2), a single-transmembrane receptor with an intrinsic guanylyl cyclase domain that generates cGMP on ligand binding. cGMP activates protein kinase G — predominantly PKG-II in chondrocytes — which inhibits the RAF–MEK–ERK arm of the MAPK cascade downstream of FGFR3. Activating the CNP–NPR-B–cGMP axis therefore antagonizes the specific over-active signal that causes the disease, which is what makes this an unusually clean mechanistic match rather than a symptomatic treatment. Native CNP-22 has a plasma half-life of roughly two to three minutes, cleared by neprilysin-mediated proteolysis and NPR-C-mediated receptor internalization. Two engineering strategies have reached approval. Vosoritide modifies the peptide: a 39-residue analog whose N-terminal extension resists neprilysin cleavage while preserving NPR-B agonism, sufficient for once-daily subcutaneous dosing. Navepegritide leaves the peptide alone and modifies its availability. The TransCon platform conjugates an unmodified CNP payload — CNP(89-126), the 38-residue form commonly written CNP-38 — to an inert methoxy-polyethylene-glycol carrier through a transient linker. While conjugated, the molecule is pharmacologically inactive and shielded from proteolysis and receptor-mediated clearance; the linker then undergoes predictable, pH- and temperature-dependent hydrolysis, liberating free unmodified CNP-38 at a controlled rate across the dosing interval. The design intent is a continuous low-level CNP exposure profile across a week rather than the daily Cmax spike and trough of an injected analog, which in principle both maintains NPR-B engagement and keeps peak concentrations — and therefore the peak vasodilatory effect that CNP-family peptides produce through NPR-B on vascular smooth muscle — lower than a bolus analog would. The preclinical foundation was laid by Breinholt and colleagues (J Pharmacol Exp Ther 2019), who characterized TransCon CNP as a sustained-release prodrug and demonstrated efficacy in FGFR3-related skeletal dysplasia models. A first-in-human Phase 1 study (Breinholt et al., Br J Clin Pharmacol 2022) established safety, tolerability, pharmacokinetics, and pharmacodynamics. The Phase 2 dose-escalation trial ACcomplisH (Savarirayan et al., EClinicalMedicine 2023; NCT04085523) tested 6 to 100 mcg/kg weekly in 57 children and selected the 100 mcg/kg dose, whose open-label extension maintained annualized growth velocity through two years. The pivotal trial, ApproaCH (Savarirayan et al., JAMA Pediatrics 2026; NCT05598320), randomized 84 treatment-naïve children aged 2 to 11 in a 2:1 ratio to 100 mcg/kg weekly or placebo for 52 weeks and met its primary endpoint with a least-squares mean annualized-growth-velocity difference of 1.49 cm/year (95% CI 1.05–1.93, p<0.001).

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Navepegritide:

• 01Adult height — the single most important open question, and unanswered for navepegritide and for the entire CNP-analog class. The approval rests on annualized growth velocity as a surrogate, and the inference from 'grows faster during childhood' to 'meaningfully taller adult' has not been demonstrated. Confirmatory trials are a condition of continued approval.
• 02Head-to-head comparison against vosoritide — none exists. The pivotal point estimates (1.49 vs 1.57 cm/year) came from separate trials in non-overlapping age ranges with heavily overlapping confidence intervals, and ApproaCH itself showed the effect varies by age, so cross-trial ranking is not supportable. Whether continuous weekly exposure has any clinical advantage over daily pulses is genuinely unknown.
• 03Non-stature complications — whether CNP-pathway therapy reduces foramen magnum stenosis, spinal stenosis, sleep apnea, or recurrent otitis media, which drive much of the real morbidity in achondroplasia. ApproaCH measured lower-limb alignment and body proportion as secondary endpoints but was not designed or powered for complication outcomes.
• 04Optimal age to start — ApproaCH found a larger growth-velocity effect in children aged 5 and over (1.8 cm/year) than under 5 (1.0 cm/year), which cuts against the intuition that earlier is always better. The infant trial in children under 2 will inform this, but the relationship between starting age and cumulative adult-height benefit is unresolved.
• 05Long-term safety across a full childhood of exposure — the longest continuous data are two years from the ACcomplisH open-label extension. Children starting at 2 could be treated for well over a decade.
• 06The hypertrichosis signal — excess hair growth occurred in 3% of treated children versus none on placebo, sometimes localized to injection sites and sometimes generalized. Neither its mechanism nor its persistence after discontinuation has been characterised.
• 07Drug interactions — the label has no interaction section. The pharmacodynamic question of additive blood-pressure lowering with vasodilators or antihypertensives has not been formally studied.
• 08Positioning against oral FGFR3 inhibition — BridgeBio's oral infigratinib reported Phase 3 results in NEJM in June 2026 using an entirely different mechanism. If an oral drug matches injectable growth outcomes, navepegritide's weekly-versus-daily advantage over vosoritide becomes much less decisive.
• 09Combination with growth hormone — the 52-week COACH result (8.69 vs 5.95 cm/year) is striking but comes from 22 children without a placebo arm. Whether the combination changes adult height, or merely front-loads growth, is untested.

Forms & Administration

YUVIWEL is supplied as a lyophilized powder in single-dose vials of 1.3 mg, 2.8 mg, and 5.5 mg (reconstituting to 2.2, 4.6, and 5.5 mg/mL respectively), each kit paired with a prefilled syringe of sterile water for reconstitution. Dosing is once weekly by subcutaneous injection, set by a weight-band table rather than a flat per-kilogram calculation: 0.88 mg weekly at 8–9.9 kg, 1.2 mg at 10–13.4 kg, 1.6 mg at 13.5–17.5 kg, 2.1 mg at 17.6–23 kg, 2.8 mg at 23.1–30.5 kg, 3.6 mg at 30.6–41.2 kg, 5 mg at 41.3–55.9 kg, 6.6 mg at 56–73.5 kg, and 8.8 mg at 73.6–90 kg; the top two bands require two kits per dose. Injection sites are the abdomen at least two inches from the navel or the thighs, with the buttocks and the back of the upper arm additionally available when a caregiver administers the dose; site rotation is advised, partly because of injection-site reactions and partly because of localized hypertrichosis. There is no required time of day, and — unlike vosoritide — no pre-dose food or fluid requirement. Reconstituted product should be used within four hours at or below 30°C. Children switching from daily vosoritide begin YUVIWEL the day after their final daily dose. All pediatric injectable therapy should be initiated and supervised by a clinician experienced in skeletal dysplasia, typically a pediatric endocrinologist or clinical geneticist, with caregiver training on reconstitution and injection technique.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

YUVIWEL is approved only for children aged 2 and older with achondroplasia and open epiphyses, and the approval is an accelerated approval based on a growth-velocity surrogate endpoint. All dosing, initiation, continuation, and discontinuation decisions for a child with achondroplasia must be made by a qualified pediatric specialist. The weight-band figures above reproduce the FDA label for reference and are not a substitute for a prescription.

Timeline of Effects

Common Questions

Who Navepegritide Is NOT For

Drug & Supplement Interactions

The YUVIWEL label contains no drug-interaction section at all — an unusual absence that reflects a lack of dedicated interaction studies rather than an established absence of interactions, and worth stating plainly rather than reading as reassurance. Navepegritide is cleared through linker hydrolysis, peptidase degradation of the released CNP payload, receptor-mediated uptake, and renal filtration of the PEG carrier, with no meaningful hepatic cytochrome P450 involvement, so classical CYP-mediated pharmacokinetic interactions are not expected. The interaction concern that is mechanistically real is pharmacodynamic and shared across the CNP class: CNP acts on NPR-B in vascular smooth muscle to raise cGMP and relax vessels, so blood-pressure-lowering agents could in principle add to that effect. In practice most children with achondroplasia are not on antihypertensives, vasodilators, nitrates, or PDE5 inhibitors, which is part of why the question has not been studied. The prodrug design should in principle blunt this concern relative to a bolus analog, since continuous low-level release avoids the daily concentration peak that drives peak vasodilation — and consistent with that, no symptomatic hypotension was observed in ApproaCH. The label nonetheless carries risk of low blood pressure as its sole warning and advises reporting dizziness, fatigue, or nausea. One combination has been studied deliberately: the Phase 2 COACH trial co-administered navepegritide with lonapegsomatropin, Ascendis's once-weekly growth hormone prodrug, without a reported safety signal over 52 weeks in 22 children. That is a small dataset and does not establish the combination as a treatment strategy. Families and clinicians should disclose all concomitant medications, over-the-counter products, and supplements to the prescribing specialist and to the specialty pharmacy.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions